GARDASIL® 9

BIOLOGICAL2 trials

Sponsors

Beijing Health Guard Biotechnology, Inc

Conditions

Human Papillomavirus Infection

Phase 3

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

Active, not recruitingNCT05662020

Beijing Health Guard Biotechnology, IncHuman Papillomavirus Infection

Start: 2022-03-23End: 2028-03-23Updated: 2022-12-27

A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine

Active, not recruitingNCT06207175

Beijing Health Guard Biotechnology, IncHuman Papillomavirus Infection

Start: 2023-11-21End: 2026-01-25Updated: 2024-01-23